282 related articles for article (PubMed ID: 26954715)
21. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
22. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Giorgi Rossi P; Lebeau A; Canelo-Aybar C; Saz-Parkinson Z; Quinn C; Langendam M; Mcgarrigle H; Warman S; Rigau D; Alonso-Coello P; Broeders M; Graewingholt A; Posso M; Duffy S; Schünemann HJ;
Br J Cancer; 2021 Apr; 124(9):1503-1512. PubMed ID: 33597715
[TBL] [Abstract][Full Text] [Related]
23. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
[TBL] [Abstract][Full Text] [Related]
24. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
25. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
27. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
[TBL] [Abstract][Full Text] [Related]
28. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
29. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
[TBL] [Abstract][Full Text] [Related]
30. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
31. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
32. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
Bargallo JE; Lara F; Shaw-Dulin R; Perez-Sánchez V; Villarreal-Garza C; Maldonado-Martinez H; Mohar-Betancourt A; Yoshizawa C; Burke E; Decker T; Chao C
J Surg Oncol; 2015 Feb; 111(2):203-7. PubMed ID: 25288020
[TBL] [Abstract][Full Text] [Related]
33. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.
Chen XH; Zhang WW; Wang J; Sun JY; Li FY; He ZY; Wu SG
Biomark Med; 2019 Feb; 13(2):83-93. PubMed ID: 30565472
[TBL] [Abstract][Full Text] [Related]
34. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
[TBL] [Abstract][Full Text] [Related]
35. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
[TBL] [Abstract][Full Text] [Related]
36. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
Mao Y; Chen XS; Liang Y; Wu JY; Huang O; Zong Y; Fang Q; He JR; Zhu L; Chen WG; Li YF; Lin L; Fei XC; Shen KW
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):502-508. PubMed ID: 28728295
[No Abstract] [Full Text] [Related]
37. Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Lee HB; Lee SB; Kim M; Kwon S; Jo J; Kim J; Lee HJ; Ryu HS; Lee JW; Kim C; Jeong J; Kim H; Noh DY; Park IA; Ahn SH; Kim S; Yoon S; Kim A; Han W
Clin Cancer Res; 2020 Dec; 26(24):6513-6522. PubMed ID: 33028590
[TBL] [Abstract][Full Text] [Related]
38. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
39. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
[TBL] [Abstract][Full Text] [Related]
40. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
